摘要:
Disclosed are compounds of Formula I: Formula (I); wherein R1, R2, R3, R4 , and X, are defined hereinbefore in the specification, which can be useful in the treatment of autoimmune and inflammatory diseases, and processes for producing said compounds.
摘要:
The present teachings provide compounds of formula I or a pharmaceutically acceptable salt, hydrate, or ester thereof, wherein: X is selected from a) -NR3-Y-, b) -O-Y-, c) -S(O)m-Y-, d) -S(O)mNR3- Y-, e) -NR3S(O)m-Y-, f) -C(O)NR3-Y-, g) -C(S)NR3-Y-, h) -NR3C(O)- Y-, i) -NR3C(S)-Y-, j) -C(O)O-Y-, k) -OC(O)-Y-, and I) a covalent bond; Y, at each occurrence, independently is selected from a) a divalent C1-10 to alkyl group, b) a divalent C2-10 alkenyl group, c) a divalent C2-10 alkynyl group, d) a divalent C1-10 haloalkyl group, and e) a covalent bond; R1 is selected from a) a C 1-10 alkyl group, b) a C3-14cycloalkyl group, c) a 3-14 membered cycloheteroalkyl group, d) a C8-14 polycyclic aryl group and e) a 5-14 membered heteroaryl group, wherein each group optionally is substituted with 1-4 -Y-R4; R2 is a C6-14 aryl group or a 5-14 membered heteroaryl group, wherein each group optionally is substituted with 1-4 groups independently selected from -Y-R4 Or -O-Y-R4. The present teachings also provide methods of making the compounds of formula I, and methods of treating autoimmune and inflammatory diseases by administering a therapeutically effective amount of a compound or compounds of formula I to a mammal including a human.
摘要:
Described herein are compounds of formula I: wherein G is and pharmaceutically acceptable salts thereof, wherein J, X, R 1 , R 2 , R 11 , R 12' and p are as defined herein. Also provided herein are methods of making the compounds of formula I, and methods of using these compounds for inhibiting or treating a pathological condition or disorder linked to or mediated by a protein kinase in a mammal.